TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE D-

NCT06241456: FT825/ONO-8250, an Off-the-Shelf, HER2 CAR-T, With or Without Monoclonal Antibodies in Advanced Solid Tumors

Sponsor: Fate Therapeutics · Phase: PHASE1 · Area: ONCOLOGY · Target Enrollment: 351 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$10,053,120

Rescue Site Savings

+$6,628,776

Unlock Full NCT06241456 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06241456 Rescue Dossier →